Jia Luo, MD

Articles by Jia Luo, MD

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC

May 5th 2025

Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.

Face-Off: Award Presentations and Event Conclusion

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

January 4th 2024

Judy concludes the event and presents the awards.

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

January 4th 2024

A debate presented on liquid biopsy versus tissue biopsy to determine front line therapy in metastatic NSCLC.

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 28th 2023

Dr. Florez leads the discussion on the association between Medicaid insurance, biomarker testing, and the outcomes in patients with advanced NSCLC.

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 28th 2023

Dr. Herbst discusses the CHRYSALIS Phase 1 trial.

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 21st 2023

An overview of results from the phase III randomized ADAURA Trial.

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 21st 2023

A review of Brigatinib versus crizotinib in ALK inhibitor-naïve advanced ALK-positive NSCLC.

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 14th 2023

A review of adagrasib in the KRYSTAL-1 trial in patients with NSCLC.

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 14th 2023

A discussion on the Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC: Phase III CROWN Study

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 7th 2023

The outcomes of the use of Sotorasib in patients with pretreated KRAS G12C mutated NSCLC.

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

ByJia Luo, MD,Narjust Florez, MD,Justin Gainor, MD,Scott J. Swanson, MD,Anne Chiang, MD ,Roy S. Herbst, MD, PhD,So Yeon Kim, MD,Justin Blasberg, MD, MPH, FACS

December 7th 2023

Highlight on the debate format, speakers, and direction to support the discussion.

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

ByJia Luo, MD,Tomasz M. Beer, MD,Julie N. Graff, MD

April 15th 2016

Here we review current therapies for nonmetastatic CRPC and discuss the recently completed and ongoing trials for this emerging disease state.

Latest Updated Articles

Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC
May 5th 2025
Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
April 15th 2016

Jia Luo, MD

Articles by Jia Luo, MD

Divarasib Combo Appears “Promising” in Pretreated KRAS G12C+ NSCLC

Face-Off: Award Presentations and Event Conclusion

Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic NSCLC

Association Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLC

Amivantamab in EGFR Exon 20 Insertion Mutated NSCLC Progression on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase 1 Study

Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA NSCLC: Updated Results From the Phase III Randomized ADAURA Trial

Brigatinib Versus Crizotinib in ALK Inhibitor-Naïve Advanced ALK-Positive NSCLC: Results on Phase 3 ALTA-1L Trial

KRYSTAL-1: Two Year Follow Up of Adagrasib Monotherapy in Patients With Advanced/Metastatic KRAS G12C Mutated NSCLC

Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients with ALK Positive Advanced NSCLC from the Phase III CROWN Study

Long Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients with Pretreated KRAS G12C-Mutated NSCLC

Face-Off: Introduction of the Non-Small Lung Cancer (NSCLC) Debate

Treatment of Nonmetastatic Castration-Resistant Prostate Cancer

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy

Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer

FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer

FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC

Achieving a “Functional Cure” With Multiple Myeloma Therapy